This is the supplier profile page of ABERA, where buyers can explore products, connect directly with the supplier for pricing inquiries.
1.1
rue victor roussin bp 14 saint brice en cogles . france
Add Favorite
Report Supplier
Business Description
Abera is developing the next generation vaccines and immunotherapies based on our proprietary vaccine delivery platform.
With the novel vaccine platform BERA, Abera can decorate Outer Membrane Vesicles (OMVs) with large amounts of antigen of one or more varieties. The OMVs enhances the immune response and antigen provides strong and broad protection.
Abera develops a pipeline of vaccine candidates based on its proprietary technology. The lead candidate is a universal pneumococcal vaccine candidate given as a nasal spray now in preparation for clinical trials. Abera also explores applications in personalized immunotherapy.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to create efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experiences into new, innovative vaccines.
OSLO/STOCKHOLM, 28 october 2024 Researchers at Abera Bioscience are set to test whether their bacterial-based platform could strengthen intranasal vaccines being developed to protect against
Business Overview
Avg Response Time
≤ 1h
Trade Capabilities
Business Terms
Trade Ability
